LTRN News and Press, Lantern Pharma Inc. From 11/01/23

Webcast to be held Wednesday, November 8th, 4:30 p.m. ET, register for the webcast here , or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN ), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR ® , with multiple clinical stage drug programs, today announced that Lantern management wi...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR ® , with multiple clinical stage drug programs, today announced that in vivo data high...

LP-184 is being studied in a first-in-human Phase 1 clinical trial, having been developed with guidance from Lantern’s AI Platform, RADR ® , as a potential therapy for a wide range of advanced solid tumors. LP-184 is one of two molecules in Lantern’s synthetic-lethal fr...

This is the second IND Clearance over the last 100 days for drug candidates that are being developed using guidance from Lantern’s AI Platform, RADR ® . LP-284 is the second of Lantern’s synthetic-lethal franchise of molecules that have shown to be synthetically lethal ...

2023-09-14 09:09:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re wondering if there is still time to invest in machine learning stocks, some recent research will provide some useful context. A recent study by WallStreetZen reve...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR ® , with multiple clinical stage drug programs, today announced that it will present posit...

Expansion of RADR ® platform adds new AI capabilities for the automated identification of new and effective combination therapy regimens for immune checkpoint inhibitors (ICI) Additional functionality includes the creation and testing of molecular signatures of ICI response and resis...

LP-184 is the first of Lantern’s drug candidates developed by leveraging Lantern’s AI platform, RADR ® US FDA previously granted LP-184 Rare Pediatric Disease Designation and Orphan Drug Designation (ODD) for the treatment of pediatric patients with ATRT Lante...

2023-08-09 17:15:39 ET Lantern Pharma press release ( NASDAQ: LTRN ): Q2 GAAP EPS of -$0.44 misses by $0.01 . Cash, cash equivalents, and marketable securities were approximately $48.0 million as of June 30. Shares +0.64% AH. For further details see: ...